Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.900
0.00 (0.00%)
Apr 29, 2026, 9:24 AM EDT - Market open
Acrivon Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -77.91 | -80.56 | -60.39 | -31.17 | -16.24 | |
| Depreciation & Amortization | 1.36 | 1.01 | 0.54 | 0.36 | 0.04 | |
| Loss (Gain) From Sale of Investments | -0.44 | -3.78 | -3.32 | -0.7 | - | |
| Stock-Based Compensation | 14.72 | 14.29 | 11.62 | 2.19 | 0.5 | |
| Other Operating Activities | 1.03 | 0.93 | 0.78 | 0.73 | 1.4 | |
| Change in Accounts Payable | 1.54 | -3.59 | 3.61 | -0.25 | 0.8 | |
| Change in Other Net Operating Assets | -3.96 | 6.02 | 4.53 | -1.29 | -0.47 | |
| Operating Cash Flow | -63.67 | -65.67 | -42.64 | -30.12 | -13.98 | |
| Capital Expenditures | -1.67 | -2.77 | -1.29 | -2.17 | -0.24 | |
| Investment in Securities | 67.77 | -49 | 52.01 | -139.51 | - | |
| Investing Cash Flow | 66.1 | -51.77 | 50.72 | -141.68 | -0.24 | |
| Issuance of Common Stock | 0 | 70.09 | 0.78 | 104.48 | 0 | |
| Repurchase of Common Stock | -0.75 | -2.52 | -1.3 | - | - | |
| Other Financing Activities | - | 53.46 | -1.03 | -2.77 | - | |
| Financing Cash Flow | -0.75 | 121.03 | -1.55 | 101.71 | 112.22 | |
| Net Cash Flow | 1.69 | 3.59 | 6.52 | -70.08 | 98 | |
| Free Cash Flow | -65.33 | -68.44 | -43.93 | -32.28 | -14.22 | |
| Free Cash Flow Per Share | -1.70 | -2.02 | -1.99 | -7.83 | -8.16 | |
| Levered Free Cash Flow | -39.54 | -39.41 | -22.33 | -20.03 | -8.79 | |
| Unlevered Free Cash Flow | -39.54 | -39.41 | -22.33 | -20.03 | -8.79 | |
| Change in Working Capital | -2.43 | 2.44 | 8.14 | -1.53 | 0.33 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.